Genomic Vision SA (G09.SG)
| Previous Close | 0.0013 |
| Open | 0.0017 |
| Bid | 0.0000 x 25000 |
| Ask | 0.0000 x 25000 |
| Day's Range | 0.0013 - 0.0017 |
| 52 Week Range | 0.0002 - 0.0163 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireGenomic Vision Announces the Opening of a Receivership Proceedings
BAGNEUX, France, November 17, 2023--Regulatory News: Genomic Vision (FR0011799907 – GV, the "Company"), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of transformed cells, announces that, following the Company’s request (press release of November 3, 2023), the Commercial Court of Nanterre, decided on Novembre 15, 2023 to open a receivership procedure.
Business WireGenomic Vision: Financial Information for the Third Quarter of 2023
BAGNEUX, France, November 14, 2023--Regulatory News: Genomic Vision (FR0011799907 – GV, the "Company"), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, today announced its revenue and cash position for the third quarter ended on September 30, 20231.
Business WireGenomic Vision Requests Receivership Proceedings
BAGNEUX, France, November 03, 2023--Regulatory News: Genomic Vision (FR0011799907 – GV, the "Company"), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of transformed cells, announces having filed today a declaration of cessation of payments ("déclaration de cessation des paiements") with the Commercial Court of Nanterre.
